J.B.Chemicals & Pharmaceuticals Ltd. (BSE: 506943) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹38,731 Cr, it ranks #241 by market cap among the 6,137 Indian listed companies on FinBizNet, and #13 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,416.10 (as of 25 Oct 2026), the share price is 4.3% below its 52-week high of ₹2,525.50 and 47.5% above its 52-week low of ₹1,638.50. The share price is up 43.0% over one year and up 17.9% over three months.
| Current Price | ₹2,416.10 |
|---|---|
| Market Cap | ₹38,731 Cr |
| BSE Code | 506943 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| Return on Equity | 18.69% |
| Return on Assets | 12.48% |
| 52-Week Range | ₹1,638.50 – ₹2,525.50 |
| 1-Year Price Change | +43.0% |
| 3-Month Price Change | +17.9% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.jbpharma.com |
| Revenue | ₹904 Cr |
|---|---|
| Net Profit | ₹101 Cr |
| Net Margin | 11.2% |
| EPS (Basic) | ₹6.35 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-anal
1. Pharmaceuticals-This segment manufactures and markets a range of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| J.B.Chemicals & Pharmaceuticals Ltd. | ₹38,731 Cr | — | 18.69% | ₹904 Cr | +43.0% |
Listed by market capitalisation. Ratios are shown for context only.
J.B.Chemicals & Pharmaceuticals Ltd. is trading at ₹2,416.10, with a market capitalisation of ₹38,731 Cr.
J.B.Chemicals & Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
J.B.Chemicals & Pharmaceuticals Ltd. has a return on equity of 18.69%.
J.B.Chemicals & Pharmaceuticals Ltd. is listed on the BSE under the scrip code 506943.
J.B.Chemicals & Pharmaceuticals Ltd.'s share price is up 43.0% over one year and up 17.9% over three months. Its 52-week range is ₹1,638.50 to ₹2,525.50.
In Q4 FY26, J.B.Chemicals & Pharmaceuticals Ltd. reported revenue of ₹904 Cr and net profit of ₹101 Cr, with basic EPS of ₹6.35 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.